Avidity Biosciences is a clinical-stage biopharmaceutical company built around its proprietary Antibody Oligonucleotide Conjugate, or AOC, platform. The company is developing a pipeline of RNA-based medicines designed to deliver oligonucleotide therapies to specific tissues, with a current focus on rare neuromuscular diseases and precision cardiology. Its lead programs include del-desiran, del-brax, and del-zota, which are being advanced toward potential commercialization. Avidity has not yet commercialized a product and has funded its operations primarily through equity financings and collaboration agreements.
−3 955,2 %
−3 650,4 %
+72,1 %
9.20
9.20
| % | |
|---|---|
| AOC platform | 0% Antibody Oligonucleotide Conjugate technology used to deliver RNA therapeutics to specific tissues and cell types. |
| Clinical-stage product candidates | 0% Lead programs in clinical development, including del-desiran, del-brax, and del-zota. |
| Preclinical and discovery pipeline | 0% Earlier-stage programs in neuromuscular, precision cardiology, and other tissue types. |
| Collaboration revenue | 100% Upfront, milestone, and service reimbursement revenue from research and license agreements. |
Avidity does not yet sell approved products, so its current counterparties are collaboration partners rather than...
Partners that provide upfront fees, milestones, and research reimbursements for AOC programs and may help advance non-core indications.
Future end users for approved therapies such as del-desiran, del-brax, and del-zota, where the company aims to address high unmet need.
Neuromuscular and cardiology specialists who would diagnose, prescribe, and monitor therapy if products are commercialized.
External service providers that support preclinical studies, clinical trials, and manufacturing of product candidates.
Third parties with established sales and distribution capabilities that could commercialize products in selected geographies or indications.
Avidity is headquartered in San Diego, California and operates as a U.S.-based biotechnology company...
Avidity's strategy is centered on proving the AOC platform and advancing its lead clinical programs in rare...
Clinical success is the main value driver because the company has no approved products or product sales yet.
The company needs sales, marketing, distribution, and launch capabilities if its first products are approved.
Broader tissue delivery could create a larger pipeline and reduce dependence on a small number of programs.
As a development-stage biotech, funding needs are high and partnerships can reduce risk and extend runway.
Avidity faces the classic risks of a clinical-stage biotech: uncertain clinical outcomes, regulatory risk, and the...
The company has three product candidates in clinical development and all other programs are preclinical or discovery-stage, so pipeline value depends on successful trials and approvals.
Avidity has incurred significant operating losses since inception and expects continued losses, so it may need additional funding to sustain development and launch plans.
The company relies on CROs, CMOs, consultants, and scientific advisors for development and manufacturing, which can affect timelines, quality, and cost.
Biopharma competition is intense and the company must protect its AOC platform and candidate-specific intellectual property to preserve value.
The pending Novartis transaction may not close on the anticipated timeline or at all, which could disrupt operations and investor expectations.
OVID · Pharmaceutical Preparations
IBIO · Pharmaceutical Preparations
BNTC · Pharmaceutical Preparations
ASMB · Pharmaceutical Preparations
APGE · Biological Products, (No Diagnostic Substances)
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
: 11/08/2026